Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Anoikis resistance drives transcriptional plasticity in pancreatic cancer

ABSTRACT: This SuperSeries is composed of the SubSeries listed below.

ORGANISM(S): Mus musculus Homo sapiens

PROVIDER: GSE202534 | GEO | 2023/04/04

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Anoikis resistance drives transcriptional plasticity in pancreatic cancer

Project description:Anoikis resistance drives transcriptional plasticity in pancreatic cancer

| PRJNA836487 | ENA

Nuclear Factor NFAT5 Governs Cellular Plasticity-Induced KRAS-Targeted Therapy Resistance in Pancreatic Cancer

Project description:This SuperSeries is composed of the SubSeries listed below.

2024-10-09 | GSE252839 | GEO

FOXA2/AP-1 drives prostate cancer lineage plasticity

Project description:This SuperSeries is composed of the SubSeries listed below.

2024-04-22 | GSE232555 | GEO

Acquired anoikis resistance mediates enhancer-driven subtype plasticity in pancreatic cancer [RNA-seq]

Project description:Genetic aberrations, including mutations or deletions in KRAS, TP53, SMAD4, and CDKN2A, are common causes of pancreatic ductal adenocarcinoma (PDA). Recent large-scale transcriptomic studies demonstrated that heterogeneous gene expressions played an essential role in determining molecular subtypes of PDA, although it remains unclear what the biological cues and consequences of distinct transcriptional programs are. Here, we describe an anoikis-induction-based experimental model that enforces the transition toward a squamous subtype of PDA cells. Characteristics of the squamous subtype, represented by aggressive behaviors, are faithfully recapitulated in vitro and in vivo, demonstrating the physiological relevance of this model. Integrated analysis of epigenome and transcriptome reveals that squamous subtype PDA cells acquire pro-angiogenic enhancer activity of which is sustained by the transcription factor TEAD2. Genetic and pharmacological inhibition of TEAD2 of these tumor cells impairs their pro-angiogenic phenotypes in vitro and cancer progression in vivo. Furthermore, we found that CD109 is a critical TEAD2 target that retains activated JAK-STAT signaling. Together, our findings implicate a TEAD2-CD109-JAK/STAT axis as a potential therapeutic vulnerability concealed in the squamous subtype-associated epigenome of pancreatic cancer cells.

2023-04-04 | GSE202532 | GEO

Acquired anoikis resistance mediates enhancer-driven subtype plasticity in pancreatic cancer [ChIP-Seq]

2023-04-04 | GSE202527 | GEO

Acquired anoikis resistance mediates enhancer-driven subtype plasticity in pancreatic cancer [ATAC-Seq]

2023-04-04 | GSE202526 | GEO

Transcriptional profiling of pancreatic cancer cell lines not expressing or over-expressing S100BP

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

2014-01-01 | E-GEOD-35199 | biostudies-arrayexpress

N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer

Project description:This SuperSeries is composed of the SubSeries listed below.

2019-08-26 | GSE117306 | GEO

Urothelial-to-Neural Lineage Plasticity Drives Progression to Small Cell Bladder Cancer